Lupus

      #EULAR2025 Abstr#OP0032 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 5 #SLE patients in Phas

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 2 weeks ago
      #EULAR2025 Abstr#OP0032 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 5 #SLE patients in Phase 1. Advantages over autologous/allogenic: -No apheresis -No conditioning chemo -Shorter hospital stays ~3days -Ability to redose in partial responder @RheumNow https://t.co/qimC94pVU1
      #AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources,
      #Easylupus is

      Bella Mehta bella_mehta

      4 months 2 weeks ago
      #AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources, #Easylupus is condensed, even more easy to read It's better to ask your patients to use it as a reliable source! #EULAR2025 @RheumNow https://t.co/FbYYm1dB8E
      eular
      SLE Preview: advances to achieve deep B-cell depletion
      4 months 2 weeks ago
      The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus. Its main principle is to induce deep B-cell depletion, with the hope to reset the B-cell aberrant immunity for a sustained clinical remission. At EULAR 2025 in Barcelona, several advances of CAR-based therapies will be presented.

      Catch up on Conference Podcasts

      ×